Changes in Left Atrial Appendage Dimensions Following Volume Loading During Percutaneous Left Atrial Appendage Closure  by Spencer, Ryan J. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 5 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 0 7 . 0 3 5Changes in Left Atrial Appendage
Dimensions Following Volume Loading
During Percutaneous Left Atrial
Appendage Closure
Ryan J. Spencer, MD, Peggy DeJong, MD, Peter Fahmy, MD, Mathieu Lempereur, MD, Michael Y.C. Tsang, MD,
Kenneth G. Gin, MD, Pui K. Lee, MD, Parvathy Nair, MD, Teresa S.M. Tsang, MD, John Jue, MD, Jacqueline Saw, MDABSTRACTFro
Ca
gra
Ab
Sci
an
the
MaOBJECTIVES This study sought to determine whether volume loading alters the left atrial appendage (LAA) dimensions
in patients undergoing percutaneous LAA closure.
BACKGROUND Percutaneous LAA closure is increasingly performed in patients with atrial ﬁbrillation and contraindi-
cations to anticoagulation, to lower their stroke and systemic embolism risk. The safety and efﬁcacy of LAA closure relies
on accurate device sizing, which necessitates accurate measurement of LAA dimensions. LAA size may change with
volume status, and because patients are fasting for these procedures, intraprocedural measurements may not be
representative of true LAA size.
METHODS Thirty-one consecutive patients undergoing percutaneous LAA closure who received volume loading during
the procedure were included in this study. After an overnight fast and induction of general anesthesia, patients had their
LAA dimensions (oriﬁce and depth) measured by transesophageal echocardiography before and after 500 to 1,000 ml of
intravenous normal saline, aiming for a left atrial pressure >12 mm Hg.
RESULTS Successful implantation of LAA closure device was achieved in all patients. The average oriﬁce size of the LAA
at baseline was 20.5 mm at 90, and 22.5 mm at 135. Following volume loading, the average oriﬁce size of the LAA
increased to 22.5 mm at 90, and 23.5 mm at 135. The average increase in oriﬁce was 1.9 mm (p < 0.0001). The depth of
the LAA also increased by an average of 2.5 mm after volume loading (p < 0.0001).
CONCLUSIONS Intraprocedural volume loading with saline increased the LAA oriﬁce and depth dimensions during LAA
closure. Operators should consider optimizing the left atrial pressure with volume loading before ﬁnal device
sizing. (J Am Coll Cardiol Intv 2015;8:1935–41) © 2015 by the American College of Cardiology Foundation.A trial ﬁbrillation (AF) is thought to accountfor 15% to 20% of all ischemic strokes and,due to an increasingly aging population, is
growing in prevalence. Studies predict that by the
year 2050, there will be between 12 and 16 million
patients with AF in the United States alone (1).
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ABBR EV I A T I ON S
AND ACRONYMS
ACP = Amplatzer Cardiac Plug
AF = atrial ﬁbrillation
CT = computed tomography
IV = intravenous
LAA = left atrial appendage
TEE = transesophageal
echocardiography
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1936with lifelong anticoagulation have been
widely sought.
Two randomized controlled trials have
shown the safety and efﬁcacy of percutaneous
left atrial appendage (LAA) closure, and this
procedure has emerged as an alternative for
patients with AF and signiﬁcant stroke risk,
who are at increased risk of bleeding (3,4).
Percutaneous LAA closure has obvious bene-
ﬁts, including removing the need for ongoingadherence to anticoagulation, eliminating moni-
toring, decreasing medication interactions, and
reducing ongoing bleeding risk. Minimizing peri-
procedural complications of percutaneous LAA
closure is critical in order to offer a favorable risk–
beneﬁt ratio to patients. These include access site
complications, pericardial effusion and tamponade,
residual leak around the device, and embolization of
the implanted device. Appropriate sizing of the
currently available implantable devices is paramount
for both procedural success and to reduce periproce-
dural complications. Choosing the correctly sized de-
vice relies on accurate measurement of LAA size.SEE PAGE 1942The 2 most widely implanted LAA closure devices
are the WATCHMAN (Boston Scientiﬁc, Natick, Mas-
sachusetts) and the Amplatzer Cardiac Plug (ACP)/
Amulet (St. Jude Medical, Plymouth, Minnesota).
Choosing the correct device size is important to ach-
ieve proper apposition of the device and its hooks
against the LAA wall. An undersized device may result
in embolization or residual leak, whereas aggressive
oversizing may cause tamponade, or device emboli-
zation due to inadequate engagement of the hooks.
Hence, accurately measuring the LAA size is integral to
safe percutaneous LAA closure. Both transesophageal
echocardiography (TEE) and computed tomography
(CT) have been used pre-procedurally to measure the
depth and oriﬁce diameter of the LAA, and been shown
to correlate reasonably well (5). Although CT is usually
undertaken in a euvolemic state, pre-procedural and
intra-procedural TEE involves at least 6 h of fasting.
This may affect the volume status of the patient, which
in turn may affect LAA size. Previous studies in ani-
mals and patients in sinus rhythm have shown the LAA
to be more compliant than the left atrium (6,7), sup-
porting a hypothesis that clinically signiﬁcant in-
creases in LAA size may occur with volume loading. A
single canine study demonstrated small increases in
LAA size after volume loading (8), leading to specula-
tion that LAA measurements used for percutaneous
closure may be affected by volume status and the
fasting state (5).We hypothesized that volume loading during the
procedure (to overcome the ﬂuid restriction pre-
procedure) affects LAA dimensions, and thus we
routinely administer intravenous (IV) normal saline
before sizing measurements. Our study aims to assess
the impact of an intravenous ﬂuid bolus on LAA size,
and thus determine whether there is clinical utility in
optimizing ﬂuid status before measuring maximum
LAA dimensions.
METHODS
Thirty-one consecutive patients who underwent
percutaneous LAA closure (with either the ACP or
WATCHMAN devices) at our center between March
2014 and May 2015 were included in this study. All
patients received IV normal saline targeting a left
atrial pressure of >12 mm Hg. Indications for LAA
closure were nonvalvular AF with contraindications
to long-term anticoagulation, with CHADS2 $1 and
CHADS-VASc $2 (in accordance with the American
College of Cardiology and the Canadian Cardiovas-
cular Society AF guidelines for oral anticoagulation)
(9,10). All patients underwent general anesthesia af-
ter a minimum of 6 hours of fasting.
A Philips IE33 echocardiography machine and X7-2t
TEE probe (Philips, Andover, Massachusetts) were
used to obtain baseline measurements of the LAA
oriﬁce diameter and depth before normal saline
administration. Measurements were taken as per the
manufacturer’s guidelines. For ACP/Amulet, the
widest landing zone was measured at w10 mm inside
the oriﬁce for ACP and w12 mm for Amulet. For
WATCHMAN, the widest anatomic oriﬁce (from the
circumﬂex artery inferiorly to a point 1 to 2 cm inside
the tip of the pulmonary vein ridge superiorly) and
the LAA depth were recorded (Figure 1). For the pur-
pose of this study, we measured the LAA oriﬁce and
depth at 90 and 135, because these usually produce
the largest dimensions; and utilized the WATCHMAN
oriﬁce deﬁnition to measure the oriﬁce diameter
(Figures 1 and 2). Measurements were taken when LAA
width was greatest, which usually occurs at end-
systole.
Following baselinemeasurements, a 500- to 1,000-ml
IV bolus of normal saline was infused. One liter was
given unless the patient had known left ventricular
dysfunction or there were pre-operative concerns of
volume overload, in which case 500 ml was given
instead. We proceeded with transseptal puncture
during the saline infusion, and the left atrial pressure
was measured after transseptal access was achieved.
After the infusion was completed, and the left atrial
pressure was >12 mm Hg, we then repeated the LAA
FIGURE 1 Measuring the Oriﬁce and Depth of the LAA for Percutaneous Closure
(A and B) A WATCHMAN device requires measuring from a point adjacent to the circumﬂex artery to the widest point 1 to 2 cm down from the
tip of the pulmonary vein ridge at 0, 45, 90, and 135. (C and D) Similar measurements are required for the ACP/Amulet devices although the
oriﬁce is deﬁned as the tip of the pulmonary vein ridge, and an extra measurement, 10 to 12 mm down from the oriﬁce, is also required.
ACP ¼ Amplatzer Cardiac Plug; LAA ¼ left atrial appendage; (A and B): Red ¼ WATCHMAN ostium measurement zone; green ¼ WATCHMAN
depth measurement; (C and D): Red ¼ echocardiographic oriﬁce; orange ¼ ACP landing zone; green =¼ACP depth measurement.
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1937measurements on TEE. Saline infusion occurred dur-
ing typical procedural steps and did not delay proce-
dural completion. Given that mechanical ventilation
may reduce pre-load, we ensured that the left atrial
pressure was>12 mmHg in addition to volume loading
alone, before repeating TEE measurements.
Device size selection was based on the widest
oriﬁce/landing zone dimensions measured post-ﬂuid
bolus, incorporating an upsize by 3 to 5 mm for ACP
and 9% to 25% for WATCHMAN. Patients then un-
derwent LAA closure with either a WATCHMAN or
ACP/Amulet, according to our previously described
protocol (11). In an effort to reduce bias and improve
accuracy, all LAA TEE images were reread utilizing a
commercially available ofﬂine workstation (Xcelera,
Philips, Andover, Massachusetts) by 1 of 3 echocardi-
ographers (R.S., M.T., J.J.) blinded to the stage of the
procedure. Only these blinded measurements were
used in this study.
STATISTICAL ANALYSIS. Descriptive statistics were
used to describe the baseline characteristics ofpatients. Continuous variables were summarized as
mean  SD or median and interquartile range. Cate-
gorical variables were summarized as frequency and
percentage. Continuous variables were compared
using the paired Student t test. Statistical tests were
2-sided, and a p value <0.05 was considered signiﬁ-
cant. Statistical analyses were performed with the
SPSS software (IBM SPSS version 20, Armonk, New
York).
RESULTS
All 31 patients had underlying nonvalvular AF with
contraindications to anticoagulation. The average age
of the patients was 77  7 years, and the mean
CHADS2 score was 3.0  1.4. Baseline characteristics
are described in Table 1. All patients achieved mean
left atrial pressure >12 mm Hg (28 of 31, or 90.3%, had
a left atrial pressure of at least 15 mm Hg) after vol-
ume loading. Left atrial pressures were not obtained
before volume loading, because all baseline TEE
FIGURE 2 LAA Measurements Made Before Closure With a WATCHMAN Device
(A) Measurements made before the ﬂuid bolus. (B) Measurements post-ﬂuid bolus. (C) Final image after WATCHMAN deployment showing
occlusion of the LAA. LAA ¼ left atrial appendage.
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1938measurements were taken before transseptal punc-
ture to minimize procedural time. All patients had 90
pre- and post-bolus images available for blinded
analysis. Four patients had post-bolus 135 images
that were either obscured by the delivery catheter or
not stored, leaving 31 90 measurements and 27 135
measurements for analysis.
The average oriﬁce size of the LAA at baseline was
20.5  4.5 mm at 90, and 22.5  4.4 mm at 135.
Following volume loading, the average oriﬁce
size of the LAA increased to 22.5  4.0 mm at 90, and
23.5  4.7 mm at 135 (Figure 3A). The average depthTABLE 1 Baseline and Procedural Characteristics
Age, yrs 76.7  6.7
Male 55%
CHADS2 score 3.0  1.4
Final LA pressure after volume, mm Hg 17.6  3.5
IV normal saline given, ml 855  227
Values are mean  SD or %.
IV ¼ intravenous; LA ¼ left atrial.of the LAA at baseline was 24.5  5.4 mm at 90, and
22.7  5.6 mm at 135. After volume loading, the
average depth of the LAA was 26.1  5.0 mm at 90,
and 25.0  5.3 mm at 135 (Figure 3B). The average
increase in oriﬁce was 1.9 mm (p < 0.0001), and in-
crease in depth was 2.4 mm (p < 0.0001) (Table 2).
Twenty-nine of the 31 patients had an increase in
width measurements after volume loading. Analysis
by sex and by age quartiles did not detect any sig-
niﬁcant interactions.
All patients proceeded to successful LAA closure
with no periprocedural stroke or major bleeding. No
pericardial effusions or congestive heart failure
occurred. Four of the 31 patients were noted to have
small peridevice leaks (<3 mm) on their procedural
TEE. Thirty of the 31 patients were discharged the
day after the procedure. One device embolization
occurred with a 24-mm ACP device. This was
discovered when routine transthoracic echocardiog-
raphy the morning after the procedure suggested an
unusual location of the device in the left atrium. This
device was successfully retrieved percutaneously
with no complication. This patient was delirious and
FIGURE 3 Graph Showing Change in LAA Oriﬁce Width and Depth
(A) Graph showing change in LAA oriﬁce width (measured at 135) after infusion of normal saline bolus. n ¼ 27 (data were not recorded for 4 patients at 135). Each line
represents 1 patient (long-dashed line represents 3 patients; short-dashed lines represent 2 patients). (B) Graph showing change in LAA depth (measured at 135)
after infusion of normal saline bolus. n ¼ 27 (data were not recorded for 4 patients at 135). Each line represents 1 patient, dashed lines represent 2 patients.
LAA ¼ left atrial appendage.
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1939combative during the evening after the procedure
and required 4-point restraints. The aggressive
physical movements in the setting of slight device
malapposition were felt to be contributing factors
leading to embolization, as opposed to inaccurate
device sizing.
DISCUSSION
In this study, we found that LAA width and depth
consistently increased by an average of w2 mm after
volume loading during general anesthesia. These re-
sults support the hypothesis that LAA size can vary
with volume loading. This size difference, although
relatively small, still represents an w10% increase in
the LAA dimensions following ﬂuid bolus. This is
clinically relevant when considering the appropriate
device size for a given patient, because this 10% sizeTABLE 2 LAA Width and Depth Measurements Before and
After Volume Loading
Before Fluid Bolus After Fluid Bolus p Value
90 width, mm 20.5  4.5 22.5  4.0 <0.001
90 depth, mm 24.5  5.4 26.1  5.0 <0.01
135 width, mm 22.5  4.4 23.5  4.7 <0.001
135 depth, mm 22.7  5.6 25.0  5.3 <0.001
Values are mean  SD.
LAA ¼ left atrial appendage.increase typically corresponds to upsizing of the
currently available devices by an entire size. For
example, the WATCHMAN device comes in 5 sizes (21,
24, 27, 30, and 33 mm) and a device 10% to 20% larger
than the measured oriﬁce width is typical chosen.
A 2-mm increase in the measured oriﬁce width is
likely to result in selecting a device that is 1 size larger
than if measurements without volume loading were
used. Theoretically, this more accurate sizing will
result in better device stability and potentially lower
residual LAA leak. Although the clinical signiﬁcance
of residual leak has not yet been established, many
believe that large residual LAA leaks can contribute to
higher stroke risk, as was seen with surgical LAA
closure (12,13).
Although the fasting state may represent the nat-
ural state for many patients in the early hours of the
day, the optimal values when choosing a closure de-
vice are the largest possible LAA dimensions. Estab-
lishing the physiological maximum width of the LAA
enables the operator to select the largest device that
can be accommodated by the LAA, which is likely to
have the least risk of leak, embolization, and perfo-
ration. Overzealous oversizing should be avoided
because this increases the risk of perforation, and
may also lead to device embolization if the hooks fail
to engage the LAA wall properly. Therefore, selecting
a device that remains 8% to 20% compressed when
the LAA is at its maximal size is of paramount
importance. Our strategy of volume loading of 500 to
PERSPECTIVES
WHAT IS KNOWN? The safety and efﬁcacy of
percutaneous LAA closure relies on accurate device
sizing, which necessitates accurate measurement of
LAA dimensions. LAA size may change with volume
status, and as patients are fasting for these proce-
dures, intraprocedural measurements may not be
representative of true LAA size.
WHAT IS NEW? This study provides evidence that
volume loading during percutaneous LAA closure in-
creases the oriﬁce width and depth of the LAA by
w2 mm, which can signiﬁcantly impact device size
selection.
WHAT IS NEXT? Further studies evaluating proce-
dural outcomes in patients undergoing LAA closure
with and without periprocedural volume loading and
optimizing left atrial pressure, will help clarify the
clinical impact of volume loading.
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19401,000 ml during the procedure and aiming for a left
atrial pressure >12 mm Hg is simple to adhere to and
tolerated by all patients. This strategy maximizes the
measurements for device selection.
Our ﬁndings suggest that a similar volume loading
strategy may be useful for the baseline pre-
procedural TEE (days to weeks before the proce-
dure) in order to optimize LAA measurements.
Because most echocardiographic laboratories require
patients to fast for TEE, the measured dimensions
may be similarly affected, and consideration should
be given to volume loading before measuring LAA
dimensions. The difference in volume status may also
explain the small differences between CT angiog-
raphy and TEE measurements seen in previous
studies (5), because most patients are not required to
restrict ﬂuids before CT.
STUDY LIMITATIONS. These ﬁndings should be
viewed in the context of the study’s limitations. Our
sample size was relatively small, and although a sig-
niﬁcant difference was found, caution is required
when studying such small groups. Accurate echocar-
diographic measurement of the LAA is challenging,
and obtaining identical views before and after volume
loading is not always possible. Although the differ-
ences seen were small, they were consistent across
the group of patients studied, and are supported by
previous studies (6–8). In an effort to reduce possible
bias, TEE measurements were made by echocardiog-
raphers experienced in assessing LAA size for percu-
taneous closure, who were blinded to the ﬂuid status
of the patient. Because we were unable to measure
pre-bolus left atrial pressure, it is possible that a few
patients may have started with an adequate volume
status, potentially explaining the smaller LAA size
change seen in some patients. From a practical
perspective, because all patients fasted before the
procedure and were likely to receive IV ﬂuid after
induction of anesthesia, delaying LAA measurements
until after ﬂuid administration and achievement of
adequate LA pressure seems prudent. Of note, sig-
niﬁcant contrast administration during the procedure
has the potential to increase LAA dimensions and
could have confounded our repeat LAA measure-
ments; however, these measurements were typically
performed before contrast administration. Finally, wewere not able to assess the effect of volume loading
on clinical outcomes, as there was no comparative
group who did not undergo volume loading.CONCLUSIONS
Given the importance of pre-implantation LAA mea-
surements for accurate device sizing and the increase
in LAA dimensions observed with volume loading in
this study, operators should consider ensuring that
patients are adequately volume loaded before making
ﬁnal measurements and device sizing choices during
percutaneous LAA closure. The clinical outcomes of
this simple intervention should be further explored in
larger prospective studies focusing on procedural
safety and efﬁcacy.
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